A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation.
Adolescent
Adult
Aged
Alleles
Child
Child, Preschool
Disease Susceptibility
/ immunology
Female
Genetic Predisposition to Disease
Genetic Variation
Graft vs Host Disease
/ epidemiology
HLA Antigens
/ genetics
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Incidence
Infant
Infant, Newborn
Linkage Disequilibrium
Male
Middle Aged
Minor Histocompatibility Antigens
/ genetics
Peptides
/ genetics
Transplantation Immunology
Transplantation, Homologous
Young Adult
genetic variation
graft-versus-host disease
hematopoietic cell transplantation
minor histocompatibility antigens
single nucleotide polymorphisms (SNPs)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
09
2021
accepted:
29
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
9
2
2022
Statut:
epublish
Résumé
Minor histocompatibility antigens (mHAg) composed of peptides presented by HLA molecules can cause immune responses involved in graft-versus-host disease (GVHD) and graft-versus-leukemia effects after allogeneic hematopoietic cell transplantation (HCT). The current study was designed to identify individual graft-versus-host genomic mismatches associated with altered risks of acute or chronic GVHD or relapse after HCT between HLA-genotypically identical siblings. Our results demonstrate that in allogeneic HCT between a pair of HLA-identical siblings, a mHAg manifests as a set of peptides originating from annotated proteins and non-annotated open reading frames, which i) are encoded by a group of highly associated recipient genomic mismatches, ii) bind to HLA allotypes in the recipient, and iii) evoke a donor immune response. Attribution of the immune response and consequent clinical outcomes to individual peptide components within this set will likely differ from patient to patient according to their HLA types.
Identifiants
pubmed: 34868058
doi: 10.3389/fimmu.2021.782152
pmc: PMC8636906
doi:
Substances chimiques
HLA Antigens
0
Minor Histocompatibility Antigens
0
Peptides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
782152Subventions
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
Copyright © 2021 Martin, Levine, Storer, Zheng, Jain, Heavner, Norris, Geraghty, Spellman, Sather, Wu and Hansen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biol Blood Marrow Transplant. 2004 May;10(5):320-7
pubmed: 15111931
Nat Commun. 2016 Jan 05;7:10238
pubmed: 26728094
Blood. 2007 Feb 15;109(4):1355-62
pubmed: 17008540
J Immunol Methods. 2020 Jan;476:112685
pubmed: 31678214
Hum Immunol. 2001 Nov;62(11):1200-16
pubmed: 11704282
Leukemia. 2016 Jun;30(6):1344-54
pubmed: 26857467
Bioinformatics. 2010 Aug 15;26(16):2069-70
pubmed: 20562413
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
Blood. 2018 May 31;131(22):2490-2499
pubmed: 29610366
Science. 2003 Sep 5;301(5638):1334-5
pubmed: 12958347
BMC Immunol. 2008 Jan 22;9:1
pubmed: 18211710
Front Pediatr. 2020 Jun 03;8:284
pubmed: 32582592
Front Immunol. 2020 Apr 17;11:659
pubmed: 32362897
Front Immunol. 2020 Aug 20;11:1804
pubmed: 32973756
Hum Immunol. 2013 Oct;74(10):1313-20
pubmed: 23806270
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17951-6
pubmed: 24082107
Blood. 2017 Feb 9;129(6):791-798
pubmed: 27872059
Blood. 2009 Mar 26;113(13):2888-94
pubmed: 19001082
Front Immunol. 2021 Apr 23;12:658372
pubmed: 33986749
Blood. 2012 Oct 4;120(14):2796-806
pubmed: 22859606
Transplant Cell Ther. 2021 Jul;27(7):591-599
pubmed: 33882342
Front Immunol. 2018 Aug 16;9:1819
pubmed: 30166983
Cell Rep. 2021 Mar 9;34(10):108815
pubmed: 33691108
Blood. 2018 Jan 4;131(1):108-120
pubmed: 29051183
Front Immunol. 2019 Jul 16;10:1625
pubmed: 31379830
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
Front Immunol. 2016 Mar 15;7:100
pubmed: 27014279
Nat Commun. 2014 Apr 09;5:3600
pubmed: 24714562
J Immunol. 2013 Dec 15;191(12):5831-9
pubmed: 24190657
Front Immunol. 2020 Feb 28;11:257
pubmed: 32184779
BMC Immunol. 2016 Jun 16;17(1):17
pubmed: 27307005
Front Immunol. 2019 Dec 20;10:2934
pubmed: 31921187
Nucleic Acids Res. 2019 Apr 8;47(6):3086-3100
pubmed: 30624716
Immunogenetics. 2011 Nov;63(11):691-701
pubmed: 21695550
Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33
pubmed: 12720215
Blood. 2011 Mar 17;117(11):3214-9
pubmed: 21263156
Nat Biotechnol. 2020 Feb;38(2):199-209
pubmed: 31844290
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Tissue Antigens. 2014 Oct;84(4):374-60
pubmed: 25262921
Front Immunol. 2020 Feb 21;11:276
pubmed: 32153583
Nat Commun. 2018 Oct 8;9(1):4128
pubmed: 30297836
Blood. 2006 Jul 15;108(2):749-55
pubmed: 16537799
Front Immunol. 2018 Oct 11;9:2284
pubmed: 30364159
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635